ajax loader

Loading...


Ride-the-Wave Strategy – Best for Stock Traders

Ride-the-Wave targets multi-day price momentum following a company’s earnings announcement (EA). With this strategy:

  1. Buy a stock one day post-EA if a stock reacts positively post-earnings:
    1. Near the close of trading the EA-day for a pre-market-EA
    2. Near the close of the following day for a post-market-EA
  2. Sell-to-close after 7-10 days, or possibly earlier if a desired price target is reached

Similarly,

  1. short a stock one day post-EA if a stock reacts negatively post-earnings:
    1. near the close of trading the EA-day for a premarket-EA
    2. near the close of the following day for a post-market-EA
  2. then buy-to-close after 7-10 days, or possibly earlier if a desired price target is reached

Important: Ride-the-Wave is predicated on significant price momentum triggered by an EA. The 7-10 day scenario is the maximum trade hold-time. If you see post EA-momentum is halted or reversed by a significant opposite move, re-evaluate your presence in the trade.

This popular StockEarnings screen below will give you a list of stocks that historically exhibit significant price momentum following an EA for the next seven days:

  1. Stocks exhibiting positive post-EA price moves are buy-candidates
  2. Stocks exhibiting negative post-EA price moves are sell/short-candidates

The screen includes those stocks whose Earnings just came out in last two days.

Screen criteria:

  1. Earnings Date Start Date : Current Date + -1 Day
  2. Earnings Date End Date : Current Date + -2 Days
  3. Predicted Move (Next Day) Max : 7%
  4. Predicted Move (On 7th Day) Min : 7%

Strategy Guideline:

  1. Buy the stock if stock has reacted positively. Short the stock if stock has reacted negatively (see above).
  2. Close the position in 7-10 days, or possibly earlier based on price move.

Volatility Crush Strategy - Best for Options Traders

The Volatility Crush strategy is used with stocks that typically experience relatively low-to-moderate price moves (≤4%) following their Earnings Announcements (EA). The basic trade idea is to sell put or call options right before the EA, collecting a credit when options premium is very high due to elevated implied volatility (IV). You then close the position right after the EA by buying the option back much cheaper due to the significant drop in IV that occurs after the mystery of the EA disappears. In assessing this trade, you need to do your homework to ensure you collect sufficient premium to make the trade worthwhile.

This trade is practical due to the low-to-moderate price-move after the EA, which generally won’t significantly affect the options price, unlike an “action” stock, which experience great price moves post-EA. With these symbols, if you’re on the right side of the price move, that’s a great thing. But if you’re on the wrong side of the move, not so great. Consequently, by minimizing the effect of the post-EA price move, you have a much better chance to profit from the reduction in IV without it being ruined by a violent price move.

For this trade, open the position either (1) the night before the EA when the company announces earnings or (2) during the EA day when it announces post-market, generally capturing IV at or close to its peak.

For this trade, open the position either (1) the night before the EA when the company announces earnings or (2) during the EA day when it announces post-market, generally capturing IV at or close to its peak.

This popular stockearnings screen will give you a list of stocks which do not react more than 4% fpost-EA. It includes only those stocks whose earnings are releasing next day.

Screen criteria:

  1. Earnings Date Start Date : Current Date + 1
  2. Earnings Date End Date : Current Date + 1
  3. Predicted Move (Next Day) Max : 4%
  4. Options Type: Weekly

Strategy Guideline:

  1. Options Strategy: Sell Call and Put
  2. Options Strike Price: Current Stock Price – (% Predicated Move x 2)
  3. Expiration Date: It should generally be the closest expiry immediately after the EA.
  4. Buy Insurance: Buying back Call and Put at Strike price which 10% lower than Sell Strike Price is optional but recommended.

Watch Video for More Detail

Volatility Rush Strategy - Best for Options Traders

The Volatility Rush takes advantage of increasing options premiums into earnings announcements (EA) caused by an anticipated rise in Implied Volatility (IV). With this strategy, Buy a Call and Put at-the-money (a long straddle) 2-3 weeks before the EA when IV is lower. Sell the position either (1) the night before the EA when the company announces earnings pre-market, or (2) during the EA day when it announces post-market, generally capturing IV at or close to its peak.

This popular screen will give you a list of stocks whose Options premiums tend to rise into Earnings. It includes only those stocks whose Earnings are at least two weeks away from today.

Screen criteria:

  1. Earnings Date Start Date : Current Date + 15 Days
  2. Earnings Date End Date : Current Date + 30 Days
  3. Predicted Move (Next Day) Min : 5%
  4. Options Type: Weekly or Monthly if that lines up with the two to three-week lead-time for entering the trade

Strategy Guideline:

  1. Buy a Straddle at or close to the money two to three weeks pre-EA.
  2. Sell the position either the night before the EA when the company announces earnings pre-market, or during the EA day when it announces post-market.
  3. Expiration date should generally be the closest expiry immediately after the EA.
  4. Straddle price should not be more 60% of predicted move.

Predicted Move (Volatility)

Similar to Implied Volatility in Options. Expected volatility % based on our Proprietary Volatility Predication Model. We are expecting that stock price will likely to reach % in either direction by the end of next trading session after Earnings are released and not necessarily the closing volatility %.

Why is it important?

    This indicator helps

  1. Knowing expected volatility in stocks after Earnings helps to decide trading stocks before Earnings Announcement.
  2. Taking Advantage of volatility collapse following Earnings Results by using Advance Options strategies such as Spread and Straddles.

Since Last Earnings

Change in share price since last Earnings release.

Why is it Important?

When share has gained more than 10% since it's last Earning release, it tends to over react to minor bad news and give up some gains if not all. So, it contains more downside volatility than upside When share has dropped more than 10% since it's last Earning release, it tends to over react to minor good news and recover some drops if not all. So, it contains more upside volatility than downside.

EPS Surprise (%)

Occurs when a company's reported quarterly or annual profits are above or below analysts' expectations. Here is the formula to derive % EPS Surprice:

Actual EPS - Estimated EPS
------------------------------------- x 100
Estimated EPS

Why is it Important?

Earnings surprises can have a huge impact on a company's stock price. Several studies suggest that positive earnings surprises not only lead to an immediate hike in a stock's price, but also to a gradual increase over time. Hence, it's not surprising that some companies are known for routinely beating earning projections. A negative earnings surprise will usually result in a decline in share price.

Next Day Price Change (%)

Next Regular trading session Closing price following Earnings result.

For After Market Close Earnings, It is a next trading day closing price. For Before Market Open Earnings, It is the same trading day closing price.

Why is it Important?

Next Day price change is a reaction of Earnings result.

APVO MENU
APVO
CLOSE

Aptevo Therapeutics Inc (APVO) News Today

Add to Watchlist (Why?)
Aptevo Therapeutics Announces Publication of a Scientific Article in Peer-Reviewed Journal, Frontiers in Aging
Aptevo Therapeutics Announces Publication of a Scientific Article in Peer-Reviewed Journal, Frontiers in Aging
September 28 2021 05:05 AM

Lead Clinical Candidate, APVO436, Recently Showed Clinical Activity and Acceptable Safety Profile in Adults with Myelodysplastic Syndrome (MDS) Article outlines a new strategy to employ APVO436 for targeting both MDS clones and immunosuppressive myeloid-derived suppressor cells in high-risk adult MDS patients SEATTLE, WA / ACCESSWIRE / September 28, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that the prestigious medical journal Frontiers in Aging, published a peer-reviewed article by Fatih Uckun, M.D., Ph.D., Chief Clinical Advisor at Aptevo who is coordinating the APVO436 clinical development program.

Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
August 17 2021 05:05 AM

Phase 1 study showed some patients with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) achieved a remission with APVO436 after failing 1-8 lines of prior therapies Data was published in the prestigious oncology journal Cancers SEATTLE, WA / ACCESSWIRE / August 17, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the publication of a peer-reviewed research article in the prestigious oncology journal Cancers . The research article reports the results of a multi-institutional Phase 1 clinical study of Aptevo's lead leukemia drug candidate APVO436 in 46 adult patients with relapsed or refractory AML or MDS.

Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights
Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights
August 12 2021 05:05 AM

SEATTLE, WA / ACCESSWIRE / August 12, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported its financial results and business highlights for the quarter ended June 30, 2021. Business Highlights Announced results from the Company's Phase 1 dose escalation trial evaluating lead ADAPTIR candidate, APVO436, for the treatment of acute myeloid leukemia and myelodysplastic syndromes (AML/MDS).

Aptevo Therapeutics
Aptevo Therapeutics' Chief Scientific Officer, Jane Gross, PhD, to Present at Upcoming Cambridge Health Institute PEGS Virtual Conference
July 16 2021 05:05 AM

SEATTLE, WA / ACCESSWIRE / July 16, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that Dr. Jane Gross, Senior Vice President of Research and Development and Chief Scientific Officer of Aptevo, will give a presentation and participate in a live interactive panel discussion at the Cambridge Health Institute PEGS Virtual Conference being hosted from Monday, July 19, 2021 - Thursday, July 22, 2021. Dr. Gross' talk, entitled "Generating Immuno-Modulatory Bispecific Therapeutic Candidates for the Treatment of Hematologic and Solid Tumors," will occur on Monday, July 19, 2021 at 11:25 am Eastern time.

Aptevo Therapeutics
Aptevo Therapeutics' Scientists to Present At Virtual Cell Engager Summit
June 30 2021 05:05 AM

SEATTLE, WA / ACCESSWIRE / June 30, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that three members of the Company's scientific team will present at the upcoming Virtual Cell Engager Summit being hosted from Tuesday, June 29, 2021 through Thursday, July 1, 2021. The conference is focused on strategies to "accelerate approval of cell engager therapies.

Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index
Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index
June 29 2021 05:05 AM

SEATTLE, WA / ACCESSWIRE / June 29, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies today announced that the company has been added to the Russell Microcap® Index at the conclusion of the 2021 annual reconstitution. Aptevo's inclusion in the index became effective after the US market opened yesterday, June 28, 2021.

Aptevo Therapeutics Inc. (APVO) Moves 8.7% Higher: Will This Strength Last?
Aptevo Therapeutics Inc. (APVO) Moves 8.7% Higher: Will This Strength Last?
June 15 2021 05:16 AM

Aptevo Therapeutics Inc. (APVO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Aptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid Leukemia
Aptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid Leukemia
May 27 2021 06:00 AM

Initiates Multi-Center, Multi-Arm Trial Using Active Dose Identified in the Dose Escalation Phase of the Trial SEATTLE, WA / ACCESSWIRE / May 27, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIRTM and ADAPTIR-FLEXTM platform technologies today announced that the company has initiated the expansion phase of lead anti-leukemia drug candidate, APVO436, in adult patients with acute myeloid leukemia (AML) with a multi-center, multi-arm trial using the active recommended dose identified in the dose escalation phase (Part 1) of the study. During Part 1, APVO436 exhibited a manageable side effect profile, encouraging single agent activity and a promising benefit to risk profile in relapsed AML patients.

Aptevo Stock Gains on Encouraging Single-Agent Activity for APVO436 In Leukemia Patients
Aptevo Stock Gains on Encouraging Single-Agent Activity for APVO436 In Leukemia Patients
May 26 2021 06:32 AM

Aptevo Therapeutics Inc (NASDAQ: APVO) has announced positive results from Phase 1 dose-escalation trial evaluating lead ADAPTIR candidate, APVO436, for acute myeloid leukemia and myelodysplastic syndromes (AML/MDS). The study met its primary endpoint of identification of an active dose level for advanced studies.

Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid Leukemia
Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid Leukemia
May 26 2021 06:00 AM

Dose Escalation Study of APVO436 Shows Favorable Safety Profile and No Severe Neutropenia, a Potentially Life-threatening Side Effect, Reported in a Significant Number of Patients Receiving CD123-Targeting Drugs Dosing Level Established For Advanced Clinical Trials SEATTLE, WA / ACCESSWIRE / May 26, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced positive results from the Company's Phase 1 dose escalation trial evaluating lead ADAPTIR candidate, APVO436, for the treatment of acute myeloid leukemia and myelodysplastic syndromes (AML/MDS). APVO436 was generally well tolerated and demonstrated a favorable side effect profile, including the absence of severe or prolonged neutropenia, an often serious condition associated with CD123-targeting therapies.

Aptevo Therapeutics Reports First Quarter 2021 Financial Results
Aptevo Therapeutics Reports First Quarter 2021 Financial Results
May 11 2021 06:00 AM

Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Dosing in Cohort 10 Ongoing SEATTLE, WA / ACCESSWIRE / May 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported its financial results for the quarter ended March 31, 2021. "We are pleased to report progress in the clinical trial of our ADAPTIR platform candidate APVO436, with the dose limiting toxicity (DLT) evaluation in cohorts 1 through 9 now completed and 44 patients enrolled to date in cohorts 1-10.

Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting
Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting
April 09 2021 06:00 AM

SEATTLE, WA / ACCESSWIRE / April 9, 2021 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIRTM and ADAPTIR-FLEXTM platform technologies, today announced that it will present two new posters at the American Association for Cancer Research Virtual Annual Meeting, to be held in two virtual sessions - Saturday, April 10th to Thursday, April 15th, 2021 and Monday, May 17th to Friday, May 21st, 2021. The posters will provide preclinical updates on APVO603 and Aptevo's newest pipeline candidate, APVO442.

Aptevo Therapeutics Reports 2020 Financial Results and Provides Business Update
Aptevo Therapeutics Reports 2020 Financial Results and Provides Business Update
March 31 2021 05:00 AM

Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Enrollment in Cohort 10 Ongoing Completes Sale of RUXIENCE Royalty Payments for Up Front Plus Milestone Payments of up to $67.5 million; Amends Non-Dilutive Term Loan Agreement SEATTLE, WA / ACCESSWIRE / March 31, 2021 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported its financial results for the year ended December 31, 2020, provided a clinical update, announced the sale of RUXIENCE royalty payments and responded to an indication of interest from Tang Capital Partners, LP ("TCP"). "We are very pleased with our performance in 2020 and believe we are well positioned for 2021 and beyond.

An Assessment On Aptevo Therapeutics
An Assessment On Aptevo Therapeutics
March 24 2021 04:05 AM

An Assessment On Aptevo Therapeutics

Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial
Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial
January 11 2021 06:00 AM

SEATTLE, WA / ACCESSWIRE / January 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today provided an update on its ongoing APVO436 phase 1 clinical trial. The Company noted that patient dosing in cohorts 1 through 8 has been completed and enrollment in cohort 9 has commenced.

Aptevo Therapeutics Inc. (APVO) Upgraded to Buy: Here
Aptevo Therapeutics Inc. (APVO) Upgraded to Buy: Here's Why
January 06 2021 10:47 AM

Aptevo Therapeutics Inc. (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aptevo: Positive Early Stage Data Makes This Highly Interesting
Aptevo: Positive Early Stage Data Makes This Highly Interesting
December 02 2020 11:52 AM

Aptevo went up hugely on positive phase 1 data in AML. The company develops bispecific antibodies against cancer.

Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development
Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development
November 16 2020 06:16 AM

LUND, Sweden and SEATTLE, Nov. 16, 2020 /PRNewswire/ -- Alligator Bioscience ("Alligator") (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy and Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a biotechnology...

Aptevo Therapeutics News: Why APVO Stock Is Falling 15% Today
Aptevo Therapeutics News: Why APVO Stock Is Falling 15% Today
November 04 2020 08:02 AM

Aptevo Therapeutics (APVO) news for Wednesday includes APVO stock taking a fall after a strong rally yesterday on clinical trial results. The post Aptevo Therapeutics News: Why APVO Stock Is Falling 15% Today appeared first on InvestorPlace.

APVO Stock Price Increases By 78.25%: Why It Happened
APVO Stock Price Increases By 78.25%: Why It Happened
November 04 2020 06:53 AM

The stock price of Aptevo Therapeutics Inc (NASDAQ: APVO) increased by 78.25% as it went from $6.30 at the close on Monday to $11.23 at the close on Tuesday. This is why it happened.

Top Stocks To Short As Nasdaq Sets New Intraday Record
Top Stocks To Short As Nasdaq Sets New Intraday Record
July 13 2020 09:13 AM

Markets took off this morning following more good news regarding coronavirus vaccines. Less-than-good earnings are expected for corporations, but it doesn't seem that way when looking at the major three indices.

All You Need to Know About Aptevo Therapeutics Inc. (APVO) Rating Upgrade to Buy
All You Need to Know About Aptevo Therapeutics Inc. (APVO) Rating Upgrade to Buy
June 30 2020 09:00 AM

Aptevo Therapeutics Inc. (APVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

Has Aptevo Therapeutics (APVO) Outpaced Other Medical Stocks This Year?
Has Aptevo Therapeutics (APVO) Outpaced Other Medical Stocks This Year?
June 30 2020 08:30 AM

Is (APVO) Outperforming Other Medical Stocks This Year?

Aptevo Therapeutics and Alligator Bioscience Present new Preclinical Data for ALG.APV-527 at the PEGS Virtual Interactive Global Summit
Aptevo Therapeutics and Alligator Bioscience Present new Preclinical Data for ALG.APV-527 at the PEGS Virtual Interactive Global Summit
June 10 2020 06:37 AM

SEATTLE and LUND, Sweden, June 10, 2020 /PRNewswire/ -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, and Alligator Bioscience AB (Nasdaq...

Why Aptevo Therapeutics Is Trading Higher Today
Why Aptevo Therapeutics Is Trading Higher Today
April 14 2020 10:16 AM

Aptevo Therapeutics Inc (NASDAQ: APVO) shares are trading higher on Tuesday, after the company announced it regained compliance with the NASDAQ listing requirements.

What Makes Aptevo Therapeutics Inc. (APVO) a New Buy Stock
What Makes Aptevo Therapeutics Inc. (APVO) a New Buy Stock
April 09 2020 09:00 AM

Aptevo Therapeutics Inc. (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous Leukemia
Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous Leukemia
December 06 2019 07:00 AM

SEATTLE, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to APVO436, a bispecific antibody candidate intended for the treatment of acute myelogenous leukemia (AML). APVO436 is currently being evaluated in a Phase 1/1b clinical trial in patients with AML and myelodysplastic syndrome (MDS).

Aptevo Therapeutics: Profitability Might Be 12 Months Away
Aptevo Therapeutics: Profitability Might Be 12 Months Away
October 08 2019 05:58 AM

Aptevo announced preliminary Q3'19 product revenue for its Hemophilia B drug IXINITY will be about $9M.

Aptevo Therapeutics Provides Corporate and Pipeline Update
Aptevo Therapeutics Provides Corporate and Pipeline Update
October 03 2019 01:02 PM

Reports Record Quarterly IXINITY® Net Revenue and New Patient Conversions  Following Launch of New 3,000 IU Assay

Aptevo Therapeutics Introduces New Adaptir™ Bispecific Antibody Candidate Intended for the Treatment of Solid Tumors
Aptevo Therapeutics Introduces New Adaptir™ Bispecific Antibody Candidate Intended for the Treatment of Solid Tumors
September 19 2019 06:00 AM

New ADAPTIR Candidate APVO603 is a Dual-Agonistic Bispecific Antibody Targeting 4-1BB and OX40

Aptevo Therapeutics: IXINITY Revenue Still The Focus
Aptevo Therapeutics: IXINITY Revenue Still The Focus
August 22 2019 01:02 PM

IXINITY revenue increased for the quarter, which is what I wanted to see.

Buy Aptevo Therapeutics Before Their Q2 Results
Buy Aptevo Therapeutics Before Their Q2 Results
July 30 2019 04:58 AM

Investors might want to pay attention to Aptevo Therapeutics over the next several weeks before the company's Q2 results.

Join over 100,000 investors who get daily notable Earnings alerts with predicted move.